Abstract
This paper examines key success factors for global and regional generics companies, including the ability to license in or acquire products. It explores the importance of business development deals to secure early, exclusive access to active pharmaceutical ingredients for patent challenges, as well as more profitable dose-form products that fuel growth. Further explanation of consolidation among global generics companies, and the limited number of independent, high-calibre active pharmaceutical ingredient manufacturers to support these companies, is provided.
Get full access to this article
View all access options for this article.